Live news related to THX PHARMA stock (FR0013286259): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on THX PHARMA mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €3,33 on Euronext Paris, down 4,45% at the last update. This page lists the articles published on THX PHARMA stock to track the share price, company announcements and any item likely to influence market perception.
The cash position published on October 22, 2026 by THX Pharma (formerly Theranexus) is linked to the Batten-1 timeline. According to the company, thir…
The publication of first-half 2026 accounts, released on September 29, does not prevent the stock from retreating this Wednesday. The decline occurs a…
For the first time since its creation, the Lyon-based company specializing in rare neurological diseases records revenue of €3,239 thousand in the fir…
THX Pharma (formerly Theranexus), a Lyon-based biopharmaceutical company specializing in rare neurological diseases, published its half-yearly report …
THX Pharma (Theranexus) and the Beyond Batten Disease Foundation have announced the issuance by the European Patent Office of a patent protecting the …
THX Pharma (Theranexus) and its partners Beyond Batten Disease Foundation and Biocodex have achieved a regulatory milestone in their Batten-1 program,…
The biopharmaceutical company has announced the appointment of an industry executive to its Board of Directors, who has contributed to over twenty pro…
The Pediatric Committee of the EMA has approved the Pediatric Investigation Plan for TX01, granting THX Pharma and Exeltis access to the PUMA procedur…
On the occasion of International Batten Disease Awareness Day, THX Pharma (Theranexus), Biocodex, and the Beyond Batten Disease Foundation announce a …
THX Pharma (formerly Theranexus) published its 2025 results on Tuesday, showing an increase in net loss (€3.0M compared to €1.8M in 2024) and a decrea…
